AU2012212088B2 - Alpha-ketoheterocycles and methods of making and using - Google Patents

Alpha-ketoheterocycles and methods of making and using

Info

Publication number
AU2012212088B2
AU2012212088B2 AU2012212088A AU2012212088A AU2012212088B2 AU 2012212088 B2 AU2012212088 B2 AU 2012212088B2 AU 2012212088 A AU2012212088 A AU 2012212088A AU 2012212088 A AU2012212088 A AU 2012212088A AU 2012212088 B2 AU2012212088 B2 AU 2012212088B2
Authority
AU
Australia
Prior art keywords
compound
mhz
nmr
heteroaryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012212088A
Other languages
English (en)
Other versions
AU2012212088A1 (en
Inventor
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2012212088A1 publication Critical patent/AU2012212088A1/en
Application granted granted Critical
Publication of AU2012212088B2 publication Critical patent/AU2012212088B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012212088A 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using Ceased AU2012212088B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161439415P 2011-02-04 2011-02-04
US61/439,415 2011-02-04
PCT/US2012/023718 WO2012106569A1 (en) 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using

Publications (2)

Publication Number Publication Date
AU2012212088A1 AU2012212088A1 (en) 2013-08-08
AU2012212088B2 true AU2012212088B2 (en) 2016-07-14

Family

ID=46603088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012212088A Ceased AU2012212088B2 (en) 2011-02-04 2012-02-03 Alpha-ketoheterocycles and methods of making and using

Country Status (6)

Country Link
US (1) US9504675B2 (enExample)
EP (1) EP2670245B1 (enExample)
JP (1) JP5871957B2 (enExample)
AU (1) AU2012212088B2 (enExample)
CA (1) CA2825700A1 (enExample)
WO (1) WO2012106569A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012212088B2 (en) 2011-02-04 2016-07-14 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using
TWI631097B (zh) 2012-07-27 2018-08-01 百健Ｍａ公司 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
GB201802326D0 (en) 2018-02-13 2018-03-28 Ucl Business Plc Gene therapy
CN113004193B (zh) * 2021-02-07 2024-10-18 兰州康鹏威耳化工有限公司 硅化合物在环合反应中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
EP2023728A4 (en) * 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
EP2049520A4 (en) 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
WO2010005572A2 (en) 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
WO2010039186A2 (en) * 2008-09-23 2010-04-08 Renovis, Inc. Compounds useful as faah modulators and uses thereof
AU2012212088B2 (en) 2011-02-04 2016-07-14 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using

Also Published As

Publication number Publication date
CA2825700A1 (en) 2012-08-09
JP5871957B2 (ja) 2016-03-01
EP2670245B1 (en) 2015-09-09
EP2670245A4 (en) 2014-07-02
EP2670245A1 (en) 2013-12-11
JP2014504648A (ja) 2014-02-24
WO2012106569A1 (en) 2012-08-09
US9504675B2 (en) 2016-11-29
US20130338196A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
CA2780433C (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
RU2634896C2 (ru) Новые модуляторы рецептора glp-1
TW202214587A (zh) 環丙基二氫喹啉磺醯胺化合物
KR102564946B1 (ko) 신규 glp-1 수용체 조절제
EP2670245A1 (en) Alpha-ketoheterocycles and methods of making and using
AU2012212088A1 (en) Alpha-ketoheterocycles and methods of making and using
EP3782991A1 (en) Novel modulators of sphingosine phosphate receptors
CN104395309B (zh) 环状桥头醚dgat1抑制剂
CN115403570B (zh) μ-阿片受体激动剂及其制备方法和在医药领域的应用
KR20110010777A (ko) 스핑고신 포스페이트 수용체의 신규한 모듈레이터
JP6985271B2 (ja) アルキニルジヒドロキノリンスルホンアミド化合物
EP3774722B1 (en) Opioid receptor modulators and products and methods related thereto
IL297139A (en) Modulators of mas-related g-protein receptor x4 and related products and methods
RU2672468C1 (ru) Производные аза-адамантанов и их применение
WO2014018859A1 (en) Klf5 modulators
US9321728B2 (en) Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired